TABLE 2.
Comparison of calculated mortality risk for non‐survivors and survivors dilated cardiomyopathy patients
| Non‐survivors (n = 70) | Survivors (n = 336) | P value | |
|---|---|---|---|
| Follow‐up time (month) | 32.1 ± 26.3 | 51.6 ± 32.1 | <0.0001 |
| In‐hospital mortality | |||
| Outcome of study population, n (%) | 4 (1.0%) | 402 (99%) | |
| Mortality risk by OPTIMIZE‐HF (%) | 2.95 ± 2.26 | 2.24 ± 1.52 | 0.01 |
| 1‐year mortality | |||
| Outcome of study population, n (%) | 19 (5.5%) | 345 (94.5%) | |
| Mortality risk by MAGGIC (%) | 13.91 ± 8.15 | 10.21 ± 5.76 | <0.0001 |
| Mortality risk by SHFM (%) | 10.82 ± 16.3 | 5.48 ± 6.14 | <0.001 |
| Mortality risk by BCN Bio‐HF (%) | 15.32 ± 15.95 | 9.9 ± 10.51 | <0.0001 |
| 2‐year mortality | |||
| Outcome of study population, n (%) | 32 (11.4%) | 281 (88.6%) | |
| Mortality risk by CHARM (%) | 32.49 ± 24.5 | 25.38 ± 19.63 | 0.002 |
| Mortality risk by GISSI‐HF (%) | 14.05 ± 10.97 | 11.68 ± 8.77 | 0.02 |
| Mortality risk by SHFM (%) | 15.23 ± 16.36 | 9.93 ± 10.22 | <0.001 |
| Mortality risk by BCN Bio‐HF (%) | 26 ± 22.18 | 18.96 ± 16.8 | <0.0001 |
| Mortality risk by EMPHASIS (%) | 5.07 ± 1.94 | 4.37 ± 1.88 | <0.0001 |
| 3‐year mortality | |||
| Outcome of study population, n (%) | 42 (17.8%) | 236 (82.2%) | |
| Mortality risk by MAGGIC (%) | 35.5 ± 25.15 | 27.08 ± 20.6 | <0.0001 |
| Mortality risk by BCN Bio‐HF (%) | 27.15 ± 13.1 | 23.8 ± 12.31 | 0.009 |
| 44‐month mortality | |||
| Outcome of study population, n (%) | 49 (23.3%) | 210 (76.7%) | |
| Mortality risk by MUSIC (%) | 45.61 ± 22.04 | 27.9 ± 16.83 | <0.0001 |
| 4‐year mortality | |||
| Outcome of study population, n (%) | 52 (26.8%) | 194 (73.2%) | |
| Mortality risk by GISSI‐HF (%) | 24.32 ± 15.32 | 22.94 ± 14.98 | 0.36 |
| Mortality risk by BCN Bio‐HF (%) | 43.59 ± 26.61 | 33.93 ± 22.41 | 0.0001 |
| 5‐year mortality | |||
| Outcome of study population, n (%) | 59 (39.9%) | 148 (60.1%) | |
| Mortality risk by SHFM (%) | 70.31 ± 23.55 | 43.25 ± 24.53 | <0.001 |
| Mortality risk by BCN Bio‐HF (%) | 42.61 ± 26.02 | 23.06 ± 17.07 | <0.0001 |
| Mortality risk by Miura et al. score (%) | 24.21 ± 11.87 | 19.43 ± 10.36 | 0.001 |
BCN Bio‐HF, Barcelona Bio‐Heart Failure; CHARM, Candesartan in Heart Failure‐Assessment of Reduction in Mortality and Morbidity; EMPHASIS‐HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; GISSI‐HF, Studio della Streptochinasi nell'Infarto Miocardico‐Heart Failure; MAGGIC, Meta‐Analysis Global Group in Chronic Heart Failure, MUSIC, MUerte Subita en Insuficiencia Cardiaca; OPTIMIZE‐HF, Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure; SHFM, Seattle Heart Failure Model.
Follow‐up time was presented as mean ± SD. The mortality in study population was presented as n (%). Predicted mortality was calculated based on scores presented as mean ± standard deviation.